As we celebrate the 10th anniversary of the Puerto Rico Consortium for Clinical Investigation (PRCCI), I find myself reflecting not only on how far our organization has come, but on what Puerto Rico itself has proven over the last decade.

When PRCCI was established as a subsidiary of the Puerto Rico Science, Technology and Research Trust, the vision was clear: strengthen Puerto Rico’s clinical research capabilities, expand opportunities for patients and investigators, and help position the Island as a trusted partner for global clinical research.

Ten years later, that vision has evolved into measurable impact.

Over the past decade, PRCCI has helped bring more than 300 clinical trial opportunities to Puerto Rico, supported over 90 clinical research contracts, and collaborated with more than 116 physicians and investigators across the Island. Today, our network includes 25 member and research sites participating in studies spanning more than 20 therapeutic areas, including oncology, neurology, cardiology, obesity, vaccines, rare diseases, pediatrics, and dermatology.

But the story behind those numbers is bigger than operational growth. What we have seen over these 10 years is Puerto Rico’s ability to compete globally through talent, quality, adaptability, and collaboration.

What lessons did PRCCI learn in Puerto Rico?

One of the most important lessons has been the value of investing in workforce development. Early on, we understood that long-term growth in clinical research would require building local expertise and creating sustainable career pathways.

Through PRCCI’s Clinical Research Coordinator training programs, we have certified 272 CRCs, developed 12 training cohorts, and trained hundreds of healthcare professionals in collaboration with organizations such as Yale YCCI, TransCelerate, Barnett International, and Boehringer Ingelheim.

That investment has helped strengthen operational excellence across the Island and create a stronger foundation for future growth.

What were the defining milestones for PRCCI in Puerto Rico?

Another defining milestone was the opening of PRCCI’s own Clinical Research Center in August 2023. For us, this represented much more than a new facility. It symbolized Puerto Rico’s growing maturity and readiness to support increasingly complex and innovative clinical studies.

And the industry has responded. Today, PRCCI collaborates with leading pharmaceutical companies, CROs, academic institutions, and healthcare organizations worldwide. We have worked with seven of the world’s ten largest pharmaceutical companies and six of the top ten CROs globally, including organizations such as Pfizer, Eli Lilly, Merck, Sanofi, IQVIA, Syneos Health, and PAREXEL.

Performance metrics have reinforced what many sponsors and collaborators have already experienced firsthand. Comparative data from Syneos Health showed PRCCI-affiliated sites achieving fewer protocol deviations, faster study activation timelines, and stronger patient enrollment performance compared to broader network averages.

These results matter because they challenge outdated assumptions about where high-quality clinical research can happen.

Puerto Rico offers a unique combination of U.S. regulatory alignment, bilingual talent, scientific expertise, diverse patient populations, and geographic accessibility. Yet beyond those advantages, what continues to drive progress here is the commitment of the people working across this field every day.

Clinical research is not only about studies and data points. It is about creating access, expanding representation, improving healthcare opportunities, and contributing to economic growth.

Through collaborations with more than 26 patient advocacy groups and initiatives such as the NIH All of Us Research Program, PRCCI has also focused on helping ensure that Puerto Rico’s population is represented in the science shaping the future of medicine.

As we begin our second decade, we are also entering a new phase of collaboration and growth. This anniversary year has already brought new partnerships with institutions such as Harvard University, the University of Massachusetts, and Nova Southeastern University, opening new opportunities in public health, nutrition, osteoporosis research, and workforce development.

For Puerto Rico, this moment is bigger than an anniversary. It is a reminder that world-class clinical research can happen here, that Puerto Rico has the capacity to continue growing as a strategic research partner, and that investing in science and innovation creates benefits that extend far beyond the research industry itself.

As the clinical research industry continues searching for diverse populations, stronger enrollment performance, operational excellence, and reliable long-term partners, Puerto Rico is increasingly demonstrating that it belongs in that conversation.

And for organizations looking toward the future of clinical research, this may be the right moment to take a closer look at what Puerto Rico has quietly been building over the past decade.